Clinical trial
A Single-arm, Open, Multi-center Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Effectiveness of XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).
NCT04622072 is registered in ClinicalTrials.gov with Sihuan Pharmaceutical Holdings Group Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open, Multi-center Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Effectiveness of XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 2, 2020
- Completion date
- April 27, 2022
- Enrollment
- 21 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer